RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Big potential clinical impact: Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-rec +, HER2 -, ax. node – breast ca who had a midrange 21-gene recurrence score (some benefit of chemotherapy in some women 50 y
RT @doctorpemm: #ASCO18 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | @NEJM #TAILORx #bcsm https://t.co/vi…
RT @veleveljkovic: According to study published in the leading medical journal, 70 % of patients who are diagnosed with the most common for…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
According to study published in the leading medical journal, 70 % of patients who are diagnosed with the most common form of #breast #cancer can safely avoid #chemotherapy https://t.co/MjWzzTsBSF https://t.co/YCfAMIWK5W PLEASE RETWEET AND DISSEMINATE TH
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @roentgen66: Los resultados del estudio TAILORx presentados en #ASCO18 permitirán evitar quimioterapia en grupo de riesgo intermedio htt…
RT @whereisdaz: Original study in NEJM: Adjuvant endocrine & chemoendocrine therapy had similar efficacy in women with hormone-receptor +ve…
RT @drtanws: One day soon hopefully for #bladdercancer #biomarker for selection of adjuvant therapy https://t.co/Y5krmULmgW
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/eAOyzoKraS
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
The @Surgery_Trials optiflapp study should help identify more targets for definitive RCT investigation such as the TAILORx trial showing non-inferiority for endocrine therapy only for mid-risk #breastcancer #plasticsurgery https://t.co/YNg2JfUuMa
RT @Fraslin: Cancer du sein: La chimiothérapie adjuvante guidée par un test d'expression de 21 gènes https://t.co/hOmnSSNxkf
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @Fraslin: Cancer du sein: La chimiothérapie adjuvante guidée par un test d'expression de 21 gènes https://t.co/hOmnSSNxkf
RT @skathire: Using a gene-expression signature test to avoid unnecessary adjuvant chemo in BrCa! Pretty striking results, 10K women rando…
RT @YuriHiranuma: Many women with early-stage breast cancer can skip chemotherapy: study https://t.co/VHYldYlmi7 Adjuvant Chemotherapy Gui…
@Fournevay @PsychoMedia L'étude est publiée ici: https://t.co/hOmnSSNxkf
Cancer du sein: La chimiothérapie adjuvante guidée par un test d'expression de 21 gènes https://t.co/hOmnSSNxkf
RT @joinPORPtoday: Exciting news in #breastcancer treatment: "The study... finds that patients who fall in the intermediate risk zone do a…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Según los autores acaba el calvario de la QT para muchas mujeres https://t.co/AW9teC5biU
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
Resultados del TAILORx impactará decisión terapéutica en muchos pacientes con cáncer de mama.El estudio comparó tratamiento en el grupo de riesgo intermedio (Oncotype RS 11-25) RE+,Her2Neu-,ganglios- y demostró que pueden ser tratados con terapia endocrina
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/FPbvgPBAHQ
RT @Monthy_A: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/6WKAoHoNWC
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
#ASCO18 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | @NEJM #TAILORx #bcsm https://t.co/vi1kihlsl1
RT @teamoncology: Here is the original article of TAILORx outcome. #asco18 #bcsm https://t.co/eXz3uFXXfw
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @YuriHiranuma: Many women with early-stage breast cancer can skip chemotherapy: study https://t.co/VHYldYlmi7 Adjuvant Chemotherapy Gui…
RT @BCTrialsANZ: TAILORx clinical trial results show no benefit from chemotherapy for women with hormone receptor (HR) positive, HER2 negat…
TAILORx clinical trial results show no benefit from chemotherapy for women with hormone receptor (HR) positive, HER2 negative, axillary lymph node-negative #breastcancer. More than 10,000 women participated in this study from six countries including Austra
RT @joinPORPtoday: Exciting news in #breastcancer treatment: "The study... finds that patients who fall in the intermediate risk zone do a…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @Dr7alaAlanazi: #TAILORx #ASCO18 "practice changing." Chemotherapy not needed for most women with early-stage breast cancer https://…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @kristinrojasmd: Prospective TailoRx results- even more women w/ER+/her2- early #breastcancer can be spared #chemotherapy NEJM https://…
RT @jesusanampa: momento histórico en el manejo de #cancer #MAMA Este estudio salvará a muchas mujeres de recibir quimioterapia en el futur…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Sugerente artículo con una nueva premisa en tratamiento del cancer de seno https://t.co/CGEPtaa07d
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
Tailored therapy! Chemo can be avoided in certain women with hormone receptors positive and Her2Neu negative breast cancer and no axillary lymph node involvement! #ASCO18 @ASBrS https://t.co/NKoez3lDaY
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
@froodie According to the paper, it's not quite that simple: https://t.co/5m7wa9b1Up
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
RT @joinPORPtoday: Exciting news in #breastcancer treatment: "The study... finds that patients who fall in the intermediate risk zone do a…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
Practice changing trial for early-stage breast cancer patients #ASCO18 https://t.co/4EYyOcg164
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @MuinJKhoury: #TAILORx: And here are the highly anticipated results in today’s @NEJM https://t.co/yY58LdZY8g #ASC018
Prospective TailoRx results- even more women w/ER+/her2- early #breastcancer can be spared #chemotherapy NEJM https://t.co/04gVq0qNdO
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Women with node-negative breast cancer with intermediate risk Oncotype dx scores can safely avoid chemotherapy. https://t.co/2gR1WVvqT7
RT @HH_Oncodr: Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer.…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @patriciaclarkmd: TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherap…
RT @DukeHFDoc: Proud of my wife Claire on on the publication of TAILORx results in @NEJM today-immediate implications for vast numbers of b…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Kudos to Dr Joe Sparano and the #TAILORx team #asco18. And to co-author Dr @DToppmeyer, #BreastCancer leader @RutgersCancer. Landmark study in personalizing care for early stage disease https://t.co/OcgpiqOZ6o
RT @m0370: 朝になってNEJMを開いたら、#ASCO18 のプレナリーのうち乳癌TAILORxのarticleが掲載されていた。 /NEJM https://t.co/NXgo8EEtn7 https://t.co/Q67KPkchES
TAILORx: 21-gene assay may identify up to 85% of women with early breast cancer who can be spared adjuvant chemotherapy. Older than 50 with score of 25 or lower, 50 or younger with a recurrence score of 15 or lower #bcsm @NEJM https://t.co/AojQsfHBUW
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Many women with early-stage breast cancer can skip chemotherapy: study https://t.co/VHYldYlmi7 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer https://t.co/gmxeWyq4eN
RT @uparikh89: Exciting results from a large prospective trial @BreastImaging @RadiologyACR @AmericanCancer https://t.co/Mqi2eeh1Pu
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @joinPORPtoday: Exciting news in #breastcancer treatment: "The study... finds that patients who fall in the intermediate risk zone do a…